NeuroBo Pharmaceuticals Inc. (NRBO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NRBO Stock Price Chart Interactive Chart >
NRBO Price/Volume Stats
|Current price||$0.43||52-week high||$6.57|
|Prev. close||$0.43||52-week low||$0.38|
|Day high||$0.45||Avg. volume||457,489|
|50-day MA||$0.72||Dividend yield||N/A|
|200-day MA||$1.65||Market Cap||11.50M|
NeuroBo Pharmaceuticals Inc. (NRBO) Company Bio
NeuroBo Pharmaceuticals Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals conducts business in the United States.
Most Popular Stories View All
NRBO Latest News Stream
|Loading, please wait...|
NRBO Latest Social Stream
View Full NRBO Social Stream
Latest NRBO News From Around the Web
Below are the latest news stories about NeuroBo Pharmaceuticals Inc that investors may wish to consider to help them evaluate NRBO as an investment opportunity.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022. Mr. Strickland will serve as Chair of the Company's Audit Committee.
If you’re willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill.
Good morning, trader!
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2021.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced that the Company has appointed Gil Price, M.D. as President and Chief Executive Officer. Dr. Price will replace Dr. Richard J. Kang, Ph.D., who is stepping down later this month to pursue other opportunities, while remaining on the Board of Directors. In the inte
NRBO Price Returns